Vivanza Biosciences Ltd
VIVANZAVivanza Biosciences Ltd
VIVANZA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 201.50 | 3.47 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.71 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Vivanza Biosciences is engaged in the business of trading of pharmaceutical products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 3.52 | 6.44 | 2.66 | 10.19 | 10.40 | 11.23 | 18.29 | 27.89 | 16.41 | ||||||||||
Raw Materials | 0.00 | 4.88 | 6.00 | 2.08 | 8.26 | 8.84 | 11.43 | 16.55 | 25.48 | 15.80 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Employee Cost | 0.00 | 0.38 | 0.09 | 0.05 | 0.30 | 0.34 | 0.25 | 0.31 | 0.45 | |||||||||||
| Selling & Administrative Expenses | 0.06 | 0.29 | 0.17 | 0.22 | 0.28 | 0.21 | 0.37 | 0.23 | 0.29 | |||||||||||
| Operating & Other expenses | 0.00 | -1.76 | -0.42 | 0.33 | 1.12 | 0.39 | -1.59 | 0.04 | 0.54 | |||||||||||
EBITDA | -0.06 | -0.27 | 0.60 | -0.02 | 0.23 | 0.62 | 0.77 | 1.16 | 1.13 | 0.61 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | ||||||||||
| PBIT | -0.06 | -0.27 | 0.60 | -0.02 | 0.23 | 0.61 | 0.76 | 1.16 | 1.12 | 0.60 | ||||||||||
| Interest & Other Items | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.37 | ||||||||||
| PBT | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.14 | 0.33 | 0.73 | 0.70 | 0.23 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.05 | 0.00 | 0.12 | 0.15 | 0.15 | ||||||||||
| Net Income | -0.06 | -0.31 | 0.20 | -0.44 | -0.21 | 0.09 | 0.33 | 0.61 | 0.55 | 0.08 | ||||||||||
| EPS | -0.03 | -0.01 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.03 | 0.14 | 0.02 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vivanza Biosciences Ltd | 29.31 | 3.47 | — |
| Sun Pharmaceutical Industries Ltd | 44.60 | 6.36 | 0.76% |
| Cipla Ltd | 28.72 | 4.42 | 0.89% |
| Torrent Pharmaceuticals Ltd | 63.38 | 15.31 | 0.90% |
Price Comparison
Compare VIVANZA with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 3.38%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 4.94%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
VIVANZA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Vivanza Biosciences declined 92.31% to Rs 0.02 crore in the quarter ended September 2024 as against Rs 0.26 crore during the previous quarter ended September 2023. Sales declined 60.63% to Rs 3.00 crore in the quarter ended September 2024 as against Rs 7.62 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.007.62 -61 OPM %3.674.20 - PBDT0.020.26 -92 PBT0.020.26 -92 NP0.020.26 -92 Powered by Capital Market - Live
Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 17 October 2024.Powered by Capital Market - Live
Net profit of Vivanza Biosciences declined 44.90% to Rs 0.27 crore in the quarter ended June 2024 as against Rs 0.49 crore during the previous quarter ended June 2023. Sales declined 73.56% to Rs 2.44 crore in the quarter ended June 2024 as against Rs 9.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales2.449.23 -74 OPM %14.756.50 - PBDT0.270.49 -45 PBT0.270.49 -45 NP0.270.49 -45 Powered by Capital Market - Live
Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
Vivanza Biosciences consolidated net profit declines 34.62% in the September 2022 quarter
Vivanza Biosciences consolidated net profit rises 23.81% in the September 2021 quarter
Vivanza Biosciences reports consolidated net profit of Rs 0.32 crore in the June 2021 quarter
Vivanza Biosciences reports consolidated net loss of Rs 0.13 crore in the March 2021 quarter
Vivanza Biosciences reports consolidated net profit of Rs 0.17 crore in the December 2020 quarter
Vivanza Biosciences reports standalone net profit of Rs 0.15 crore in the December 2020 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 60%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 0.01%